SAGE - Sage Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
120.25
-4.57 (-3.66%)
At close: 4:00PM EDT

120.25 0.00 (0.00%)
After hours: 4:00PM EDT

Stock chart is not supported by your current browser
Previous close124.82
Open124.35
Bid110.00 x 800
Ask129.91 x 800
Day's range120.14 - 124.35
52-week range59.57 - 195.97
Volume245,354
Avg. volume348,700
Market cap5.611B
Beta (3Y Monthly)3.45
PE ratio (TTM)N/A
EPS (TTM)-5.57
Earnings date30 Jul 2018 - 3 Aug 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est217.40
Trade prices are not sourced from all markets
  • Insys Therapeutics: Performance and Estimates for Q3
    Market Realist8 days ago

    Insys Therapeutics: Performance and Estimates for Q3

    Insys Therapeutics (INSY) is a specialty pharmaceuticals company focused on developing cannabinoids and sprays. It reported EPS of -$0.37 on revenues of $23.47 million in the second quarter of 2018.

  • Here Are the Key Products in Sage’s GABA Receptor Portfolio
    Market Realist22 days ago

    Here Are the Key Products in Sage’s GABA Receptor Portfolio

    As discussed earlier, Sage Therapeutics’ (SAGE) portfolio includes products under development for the treatment of life-threatening central nervous system (or CNS) disorders through two different programs: GABA receptor systems and NMDA receptor systems.

  • A Look at Sage Therapeutics’ NMDA Receptor Portfolio
    Market Realist24 days ago

    A Look at Sage Therapeutics’ NMDA Receptor Portfolio

    As discussed earlier, Sage Therapeutics (SAGE) is focused on the development of products for the treatment of life-threatening central nervous system (or CNS) disorders. The products under development include SAGE-718 and SAGE-904.

  • How Does Sage Therapeutics’ Product Portfolio Look in September?
    Market Realist24 days ago

    How Does Sage Therapeutics’ Product Portfolio Look in September?

    Sage Therapeutics’ (SAGE) product portfolio includes products under development for the treatment of various rare and life-threatening central nervous system disorders.

  • What Do Analysts Recommend for Sage in September?
    Market Realist24 days ago

    What Do Analysts Recommend for Sage in September?

    Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company, is developing medicines for the treatment of life-altering central nervous system disorders like major depressive disorder, Parkinson’s disease, postpartum depression, and others.

  • Business Wirelast month

    Sage Therapeutics to Present at Morgan Stanley 16th Annual Global Healthcare Conference

    Sage Therapeutics  , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that the Company will present at the Morgan Stanley 16th Annual Global Healthcare Conference on Wednesday, September 12, 2018 at 01:40 P.M.

  • Business Wirelast month

    Sage Therapeutics Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

    Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on September 4, 2018, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 145,000 shares of its common stock to 63 new employees under Sage’s 2016 Inducement Equity Plan. The 2016 Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Sage (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Sage, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.

  • Alkermes: Analysts’ View in September
    Market Realistlast month

    Alkermes: Analysts’ View in September

    Alkermes (ALKS) anticipates the net revenues in fiscal 2018 to be $957.0 million–$1.0 billion. Alkermes estimates the GAAP (generally accepted accounting principle) net income to be -$210.0 million to -$240.0 million, while the GAAP EPS is expected to be -$1.35 to -$1.55. Alkermes expects the non-GAAP net income to be between -$10 million and $20 million. The company also estimates the non-GAAP EPS to be between -$0.06 and $0.12.

  • Investor's Business Dailylast month

    This Biotech's Drug Had No 'Red Flags' In Study — Will FDA Panel Agree?

    Sage Therapeutics' experimental postpartum depression treatment didn't have any "red flags" in a recent publication, an analyst said Tuesday.

  • Business Wirelast month

    Sage Therapeutics Announces The Lancet Publishes Integrated Data from Pivotal Trials for Brexanolone Injection in Postpartum Depression

    Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced The Lancet has published an integrated analysis across three, double-blind, randomized, placebo-controlled studies of brexanolone injection in women with postpartum depression (PPD). This new analysis, published for the first time, demonstrated significant and clinically meaningful reductions in HAM-D total score, a common measure of depression severity, following treatment with brexanolone 90 µg/kg/h at the primary timepoint of 60 hours compared with placebo.

  • Considering Incyte’s Revenue Trend in Q2 2018
    Market Realist2 months ago

    Considering Incyte’s Revenue Trend in Q2 2018

    Incyte’s (INCY) consolidated revenue increased to $521.51 million in the second quarter compared to $326.44 million in the second quarter of 2017.

  • Business Wire2 months ago

    Sage Therapeutics Announces Second Quarter 2018 Financial Results and Highlights Pipeline and Business Progress

    Conditional acceptance granted by U.S. Food and Drug Administration for the proprietary name ZULRESSO™ for Sage’s intravenous formulation of brexanolone

  • Business Wire2 months ago

    Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on August 1, 2018, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 93,600 shares of its common stock to 16 new employees under Sage’s 2016 Inducement Equity Plan. The 2016 Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Sage (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Sage, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.

  • Business Wire2 months ago

    Sage Therapeutics to Present at Canaccord 38th Annual Growth Conference

    Sage Therapeutics  , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that the Company will present at the Canaccord 38th Annual Growth Conference on Wednesday, August 8, 2018 at 11:00 A.M.

  • FDA Approves United Therapeutics’ Implantable System for Remodulin
    Market Realist2 months ago

    FDA Approves United Therapeutics’ Implantable System for Remodulin

    Today, the FDA approved United Therapeutics’ (UTHR) new drug application for its Implantable System for Remodulin (or ISR).

  • Business Wire3 months ago

    Sage Therapeutics to Report Second Quarter 2018 Financial Results on Tuesday, August 7, 2018

    Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that the company will host a conference call and live webcast on Tuesday, August 7, 2018 at 8:00 A.M.

  • Sage Therapeutics’ NMDA Receptor–Based Products
    Market Realist3 months ago

    Sage Therapeutics’ NMDA Receptor–Based Products

    Sage Therapeutics (SAGE) is focused on the development of the products for the treatment of life-threatening central nervous system (or CNS) disorders. One of the products under development, SAGE-718, is based on its NMDA Receptor program.

  • Sage Therapeutics’ Product Portfolio in July
    Market Realist3 months ago

    Sage Therapeutics’ Product Portfolio in July

    Sage Therapeutics’ (SAGE) product portfolio includes products under development for the treatment of various rare and life-threatening central nervous system disorders. The chart below shows the products under development, based on the drug discovery programs for Sage Therapeutics. The company classifies its products into two programs: GABA receptors and NMDA receptors. 

  • Sage Therapeutics: Analysts’ Estimates and Recommendations
    Market Realist3 months ago

    Sage Therapeutics: Analysts’ Estimates and Recommendations

    Sage Therapeutics (SAGE) is a clinical-stage biopharmaceutical company. Sage Therapeutics develops medicines for the treatment of life-altering central nervous system disorders such as Parkinson’s disease and postpartum depression.

  • Cramer Remix: Investors can't see the reality of this market
    CNBC3 months ago

    Cramer Remix: Investors can't see the reality of this market

    Jim Cramer makes the case to value the market just as it is.

  • 3 Top Biotech Stocks to Buy for the 2nd Half of 2018
    Motley Fool3 months ago

    3 Top Biotech Stocks to Buy for the 2nd Half of 2018

    Consider putting these large-cap, mid-cap, and small-cap biotech stocks on your buy list.

  • Business Wire3 months ago

    Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on July 2, 2018, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 129,000 shares of its common stock to 31 new employees under Sage’s 2016 Inducement Equity Plan. The 2016 Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Sage (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Sage, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.

  • SAGE Therapeutics’ NMDA Receptor–Based Portfolio
    Market Realist4 months ago

    SAGE Therapeutics’ NMDA Receptor–Based Portfolio

    As discussed, SAGE Therapeutics (SAGE) is focused on the development of products for the treatment of life-threatening central nervous system disorders.

  • SAGE Therapeutics’ GABA Receptor–Based Portfolio
    Market Realist4 months ago

    SAGE Therapeutics’ GABA Receptor–Based Portfolio

    As we discussed earlier, SAGE Therapeutics’ (SAGE) portfolio includes the products it has under development for the treatment of life-threatening central nervous system disorders based on either GABA (gamma-Aminobutyric acid) or NMDA (N-methyl-D-aspartate) receptor systems.

  • A Look at SAGE Therapeutics’ Product Portfolio
    Market Realist4 months ago

    A Look at SAGE Therapeutics’ Product Portfolio

    SAGE Therapeutics (SAGE) includes two different programs based on the modulation of GABAA (gamma-Aminobutyric acid) and NMDA (N-methyl-D-aspartate) receptors for the treatment of life-threatening central nervous system disorders. Let’s have a look at the details of these programs.